We originally wrote about this topic here NMDA Receptor Modulators for Depression. There are now several companies interested in bringing a variety of NMDA drugs into the clinic, either as mono-therapy or coupled with enhancers. Let's have a look at some of the companies, their drug, and indications that they are targeting.
Avanir: Otsuka
Avanir: Otsuka
AVP-786 Dextromethorphan + Quinidine
Ph 3 Agitation in Alzheimer's Disease
Ph 2 Residual Schizophrenia
Ph 2 Major depressive disorder (adjunct)
Axsome: AXSM
Ph 3 Agitation in Alzheimer's Disease
Ph 2 Residual Schizophrenia
Ph 2 Major depressive disorder (adjunct)
Axsome: AXSM
AXS-05 Dextromethorphan + Bupropion
Ph 3 Treatment resistant depression
Ph 1 Agitation in Alzheimer's Disease
Cerecor: CERC
CERC-301 NR2B Specific NMDA antagonist oral
Ph 2 Major depressive disorder (adjunct)
JNJ / Janssen
Esketamine intranasal
Phase 3 adjunct with anti-depressant for TRD
Naurex: Allergan
NMDA receptor partial agonist with selective properties
Ph 2 NRX-1074 IV
Ph 1 NRX-1074 Oral
Ph 3 GLYX-13 (Rapastinel) Weekly IV Major Depressive disorder
Vistagen: VSTA
AV-101 NMDA selective antagonist oral
Ph 2 AV-101 Major depressive disorder
Over the next couple years, we should see some meaningful clinical readouts from some of these companies. Potentially NMDA drugs may provide for a more efficacious and safer, sustainable therapy, aside from current antidepressants for some of the above indications. Thank you for reading.
Cerecor: CERC
CERC-301 NR2B Specific NMDA antagonist oral
Ph 2 Major depressive disorder (adjunct)
JNJ / Janssen
Esketamine intranasal
Phase 3 adjunct with anti-depressant for TRD
Naurex: Allergan
NMDA receptor partial agonist with selective properties
Ph 2 NRX-1074 IV
Ph 1 NRX-1074 Oral
Ph 3 GLYX-13 (Rapastinel) Weekly IV Major Depressive disorder
Vistagen: VSTA
AV-101 NMDA selective antagonist oral
Ph 2 AV-101 Major depressive disorder
Over the next couple years, we should see some meaningful clinical readouts from some of these companies. Potentially NMDA drugs may provide for a more efficacious and safer, sustainable therapy, aside from current antidepressants for some of the above indications. Thank you for reading.
